MedTrace Logo

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

NCT04643470 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2024-11-29

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis

Conditions

Interventions

DRUG

Zanubrutinib

Administered as specified in the treatment arm

DRUG

Placebo

Placebo to match zanubrutinib

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Zhen Yao, MD · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2024-02-26
Completion
2024-08-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04643470 on ClinicalTrials.gov